Dr. Eric P. Suan, M.D.
Ophthalmology (Ophthalmology Physician)
6115 Falls Rd, Ste 300
Baltimore, MD 21209
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,071
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Yale University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MD license D0051444 · PA license MD-039313-E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Associated Retinal Consultants LLC (117 clinicians)
- The Retina Group of Washington PLLC (84 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,071
- Services billed
- 32,863
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 4,140 | 17 |
| Injection, aflibercept, 1 mg | 3,070 | 269 |
| Established patient complete exam of visual system | 2,831 | 942 |
| Injection of drug into eye | 2,308 | 467 |
| Imaging of retina | 1,850 | 544 |
| Injection, ranibizumab, 0.1 mg | 1,747 | 81 |
| Photography of the retina | 1,155 | 907 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 825 | 28 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 721 | 28 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 638 | 62 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Baltimore, MD | 55 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 26 payments worth $3,829 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $2,653 |
|---|---|
| Genentech, Inc. | $300 |
| Regeneron Pharmaceuticals, Inc. | $298 |
| Apellis Pharmaceuticals, Inc. | $238 |
| Genentech USA, Inc. | $175 |
| AbbVie Inc. | $118 |
| Ani Pharmaceuticals, Inc. | $25.11 |
| Astellas Pharma US Inc | $21.11 |
| Compensation for services other than consulting (speaking, faculty) | $2,348 |
|---|---|
| Food and Beverage | $1,481 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,348 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 6 companies. The companies reported $2,398,243 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Ma…
Novartis Pharmaceuticals Corporation - Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Novartis Pharmaceuticals Corporation - A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-R…
Apellis Pharmaceuticals, Inc. - A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)
Genentech, Inc. - A phase iii multicenter observation comparator study of the efficacy safety and pharmacokinetics
Genentech, Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.